View allAllogeneic Cell SourcingCell Collection NetworkCell Therapy Supply ChainClinical Trials SupportIndustry StandardizationOutcomes ReportingSales Sheets
Sort by dateSort by name
DescendingAscending
Webinar

When does outsourcing autologous collection center qualification and the cell therapy supply chain make sense?

Allogeneic Cell Sourcing, Cell Collection Network, Clinical Trials Support, Industry Standardization

View Webinar The first autologous CAR-T therapy was approved in 2017, and the industry has since gained substantial operating experience, treating tens of thousands of patients globally. Some drug sponsors have developed in-house teams to manage, improve, and maintain the infrastructure needed for these complex therapies, while others have opted to outsource these responsibilities. The…

Webinar

Using Patient Outcomes Data to Inform and Advance the Development of Emerging Cell and Gene Therapies

Outcomes Reporting

View this on-demand webinar for an in-depth discussion on patient outcomes tracking through registries and how leveraging patient outcomes data collected from the first-generation of approved cell and gene therapies can inform the advancement of future cell and gene therapy products. Also included is a Q&A session between live webinar attendees and the following experts:…

Webinar

Understanding Donor Characteristics to Improve Allogeneic Cell Therapy Outcomes for All

Allogeneic Cell Sourcing

Can donor-reported characteristics, like race and ethnicity, impact data quality for allogeneic cell therapies? That’s one of the questions our expert panelists will discuss during our upcoming webinar. You’ll walk away with a better understanding of:  Efficiencies in donor selection to reduce uncertainties about HLA matching and improve allogeneic cell therapy outcomes  HLA complexity in cell source selection …

Webinar

Understanding and leveraging cord blood bank capabilities and practices in cell therapy development

Allogeneic Cell Sourcing, Cell Collection Network, Clinical Trials Support, Industry Standardization

View Webinar The cord blood banking industry has been around for over 30 years, focusing on acquiring units for use in hematopoietic stem cell transplant. Recent research indicates that cord blood can be a valuable source of naïve cells for cell therapy manufacturing. Cord blood banks are evolving their processes to accommodate the use of…

UK Review and Recommendations on the Procurement of Starting Materials by Apheresis for ATMP Manufacture

Cell Collection Network, Cell Therapy Supply Chain, Industry Standardization

To ensure safe, high-quality Advanced Therapy Medicinal Products (ATMPs) are delivered to patients, procurement activities must be standardized when possible. Standardization also supports efficiency and reduces the risk for error while meeting regulatory and accreditation requirements. Download the UK Review and Recommendations on the Procurement of Starting Materials by Apheresis for ATMP Manufacture for insights…

Webinar

The role of AI in predicting stem cell donor availability

Clinical Trials Support, Outcomes Reporting

View Webinar For allogeneic cell therapy developers, donor availability is a critical factor. Without a donor, there is no therapy. Watch this webinar to learn how groundbreaking AI-based approaches, like the NMDPSM Donor Readiness Score, can predict the availability of every registered donor and evaluate the predictive power during donor selection.  Our expert panel will explain how to:…

The EBMT/EHA CAR-T Cell Handbook

Cell Collection Network, Cell Therapy Supply Chain, Industry Standardization

A joint venture between the European Society of Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), the CAR-T Cell Handbook offers clinical care applications for health care professionals in the EU that treat patients with CAR-T cell therapies. Download the guide for insights into many aspects of CAR-T cell therapies including: The…